Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kerstin Pfister

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Oncology Research and Treatment|February 25, 2025
Will Minimal Residual Disease Monitoring Be Part of Routine Surveillance?Kerstin Pfister, Henning Schäffler, Sophia Huesmann, et al.
Plos One|September 9, 2025
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivorsTatjana Braun, Sophia Huesmann, Kerstin Pfister, et al.
Plos One|November 19, 2025
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapyKerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, et al.
International Journal of Cancer|April 29, 2026
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical TrialManuel Hörner, Henning Schäffler, Lothar Häberle, et al.
International Journal of Cancer|June 2, 2025
Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patientsKathrin Niedermayer, Henning Schäffler, Georgios Vlachos, et al.
International Journal of Molecular Sciences|September 13, 2025
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast CancerKerstin Pfister, Sophia Huesmann, Angelina Fink, et al.
Geburtshilfe Und Frauenheilkunde|September 4, 2024
Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast CentersHenning Schäffler, Dorothee Jakob, Sophia Huesmann, et al.
Cancers|August 12, 2023
Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer-Real-World Data from Two Large German Breast CentersDominik Dannehl, Tobias Engler, Léa Louise Volmer, et al.
International Journal of Molecular Sciences|November 25, 2023
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer CentersHenning Schäffler, Franziska Mergel, Kerstin Pfister, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Oncology Research and Treatment|February 25, 2025
Will Minimal Residual Disease Monitoring Be Part of Routine Surveillance?Kerstin Pfister, Henning Schäffler, Sophia Huesmann, et al.
Plos One|September 9, 2025
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivorsTatjana Braun, Sophia Huesmann, Kerstin Pfister, et al.
Plos One|November 19, 2025
Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapyKerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, et al.
International Journal of Cancer|April 29, 2026
Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical TrialManuel Hörner, Henning Schäffler, Lothar Häberle, et al.
International Journal of Cancer|June 2, 2025
Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patientsKathrin Niedermayer, Henning Schäffler, Georgios Vlachos, et al.
International Journal of Molecular Sciences|September 13, 2025
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast CancerKerstin Pfister, Sophia Huesmann, Angelina Fink, et al.
Geburtshilfe Und Frauenheilkunde|September 4, 2024
Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast CentersHenning Schäffler, Dorothee Jakob, Sophia Huesmann, et al.
Cancers|August 12, 2023
Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer-Real-World Data from Two Large German Breast CentersDominik Dannehl, Tobias Engler, Léa Louise Volmer, et al.
International Journal of Molecular Sciences|November 25, 2023
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer CentersHenning Schäffler, Franziska Mergel, Kerstin Pfister, et al.
Pageof 2